Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Reexamination Certificate
2005-09-13
2010-10-26
Harris, Alana M. (Department: 1643)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
C424S093100, C424S093200, C424S093210, C424S184100, C424S190100, C424S192100, C424S207100, C424S210100, C424S234100, C424S237100
Reexamination Certificate
active
07820180
ABSTRACT:
This invention provides methods of treating and vaccinating against an antigen-expressing tumor and inducing an immune response against a sub-dominant epitope of antigen, comprising a fusion of an LLO fragment to the antigen or a recombinantListeriastrain expressing the antigen. The present invention also provides recombinant peptides comprising a listeriolysin (LLO) protein fragment fused to a Her-2 protein or fragment thereof, recombinantListeriastrains expressing a Her-2 protein, vaccines and immunogenic compositions comprising same, and methods of inducing an anti-Her-2 immune response and treating and vaccinating against a Her-2-expressing tumor, comprising same.
REFERENCES:
patent: 4458066 (1984-07-01), Caruthers et al.
patent: 4521382 (1985-06-01), Kessick
patent: 4777239 (1988-10-01), Schoolnik et al.
patent: 4816253 (1989-03-01), Likhite et al.
patent: 5262177 (1993-11-01), Brown et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5681570 (1997-10-01), Yang et al.
patent: 5824538 (1998-10-01), Branstrom et al.
patent: 5830702 (1998-11-01), Portnoy et al.
patent: 5858682 (1999-01-01), Gruenwald et al.
patent: 5877159 (1999-03-01), Powell et al.
patent: 6015567 (2000-01-01), Hudziak et al.
patent: 6017705 (2000-01-01), Lurquin et al.
patent: 6051237 (2000-04-01), Paterson
patent: 6099848 (2000-08-01), Frankel et al.
patent: 6306404 (2001-10-01), LaPosta et al.
patent: 6479258 (2002-11-01), Short
patent: 6521449 (2003-02-01), Polack et al.
patent: 6565852 (2003-05-01), Paterson
patent: 6740516 (2004-05-01), Savitzky et al.
patent: 6767542 (2004-07-01), Paterson et al.
patent: 7588930 (2005-06-01), Paterson et al.
patent: 7135188 (2006-11-01), Paterson
patent: 2003/0028206 (2003-02-01), Shiber
patent: 2003/0202985 (2003-10-01), Paterson
patent: 2003/0220239 (2003-11-01), Simard et al.
patent: 2004/0228877 (2004-11-01), Dubensky et al.
patent: 2005/0118184 (2005-06-01), Paterson et al.
patent: 2005/0129715 (2005-06-01), Paterson et al.
patent: 2006/0051380 (2006-03-01), Schulick et al.
patent: 2006/0093582 (2006-05-01), Paterson et al.
patent: 2006/0104991 (2006-05-01), Paterson et al.
patent: 2006/0121053 (2006-06-01), Sweeney et al.
patent: 2006/0205067 (2006-09-01), Paterson et al.
patent: 2006/0210540 (2006-09-01), Paterson et al.
patent: 2006/0233835 (2006-10-01), Paterson et al.
patent: 0 902 086 (1999-03-01), None
patent: WO 90/12594 (1990-11-01), None
patent: WO 92/20356 (1992-11-01), None
patent: WO 93/15212 (1993-08-01), None
patent: WO 94/17192 (1994-08-01), None
patent: WO 96/14087 (1996-05-01), None
patent: WO 96/34631 (1996-11-01), None
patent: WO 98/48026 (1998-10-01), None
patent: WO 99/06544 (1999-02-01), None
patent: WO 99/07861 (1999-02-01), None
patent: WO 99/10496 (1999-03-01), None
patent: WO 01/27295 (2001-03-01), None
patent: WO 01/72329 (2001-10-01), None
patent: WO 03/092600 (2003-11-01), None
patent: WO 2004/006837 (2004-01-01), None
Renard, V. et al. The Journal of Immunology, 171: 1588-1595, 2003.
Paterson, Y., Immunologic Research, 27(2-3): 451-462, 2003, June.
Beatly, Dissertation Abstracts Interntational, 2000, 61/10B:5224 Abstract Only.
Burnham, Drug Discovery Today, Jan. 2003, 8/2:54-55.
Gunn et al, J. Immunology, 2001, 167: 6471-6479.
Gunn, Dissertaiton Abstracts International, 2001, 62/5B:2244 Abstract Only.
Harty, et al, Current Opinion in Immunology, 1996, 8: 526-530.
Hu, et al, J. Immunology, 172: 1595-1601, 2004.
Kerksiek, et al, Current Opinion in Immunology, 1999. 11:40-405.
Lara-Tejero, et al, Current Opinion in Immunology, 2004, 7: 45-50.
Mandal, et al, BBA, 2002, 1563: 7-17.
Paterson, et al, Current Opinion in Immunology, 1996, 8:664-669.
Shen, et al, Current Opinion in Immunology, 1998, 10: 450-458.
Gunn, et al, TRENDS in Microbiology, Apr. 2001, 9/4: 161-162.
Ikonomidis, et al, J. Exp. Med., Dec. 1994, 180: 2209-2218.
Lamikanra, et al, J. Virology, Oct. 2001, 75/20:9654-9664.
Pan, et al, Cancer Research, 1999, 59: 5264-5269.
Peng, et al, J. Immunology, 2004, 172: 6030-6038.
Radford, et al, Gene Therapy, 2002, 9: 1455-1463.
Radford, et al, Int. J. Cancer, 2003, 105: 811-819.
Barry, et al (1992) “Pathogenicity and immunogenicity of Listeria monocytogenes small-plaque mutants defective for intracellular growth and cell-to-cell spread.” Infection and Immunity 60 (4): 1625-32.
Schafer, et al (1992) “Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine.” J Immunology, 149(1) 53-59.
Bast, et al (1975) “Antitumor activity of bacterial infection. II. effect of Listeria monocytogenes on growth of a guinea pig hepatoma.” J Natl. Cancer Inst., 54(3): 757-761.
Brasseur, et al (1992) “Human gene MAGE-1, which codes for a tumor-rejection antigen, is expressed by some breast tumors.” Int. J Cancer 52(5):839-841.
Chamberlain, et al (2000) “Innovations and strategies for the development of anticancer vaccines.” Expert Opinion on Pharmacotherapy, 1(4): 603-614.
Scardino, et al (2002) “HER-2
eu and hTERT Cryptic Epitopes as Novel Targets for Broad Spectrum Tumor Immunotherapy.” The Journal of Immunology, vol. 168, 5900-5906.
Disis, et al (1996) Peptide-Based, but Not Whole Protein, Vaccines Elicit Immunity to HER-2
eu, an Oncogenic Self Protein. The Journal of Immunology, vol. 156, 3151-3158.
Coussens, et al (1985)“Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu Oncogene.” Science. vol. 230, 1132-1139.
Adams et al. (1992) “Cre-loxrecombination inEscherichia colicells. Mechanistic differences from the in vitro reaction.”J. Mol. Biol. 226:661-673.
Allison et al. (1997) “Cloning and characterization of a Prevotella melaninogenica hemolysin.”Infect Immun. 65(7):2765-71.
Amici et al, “DNA vaccination with full-length or truncated Neu induces protective immunity against the development of spontaneous mammary tumors in HER-2
eu transgenic mice” Gene Therapy (2000) 7, 703-706.
An et al. (1996) “A recombinant minigene vaccine containing a nonameric cytoxic-T-Lymphocyte epitope confers limited protection against Listeria monocytogenes infection”Infect. Immun64,(5):1685-1693.
Anderson (1998) “Human gene therapy.”Nature. Apr. 30;392(6679 Suppl):25-30.
Angelakopoulos et al. (2002) “Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation.”Infect Immun. 70(7):3592-601.
Angelov et al., “Therapeutic vaccine for acute and chronic motor neuron diseases: implication for amyotrophic lateral sclerosis” PNAS Apr. 15, 2003 vol. 100 No. 8 4790-4795.
Attwood et al. (2000) “The Babel of Bioinformatics”Science290(5491):471-473.
Awwad (1989) “Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.”Cancer Res. 49(7): 1649-1654.
Bear (1986) “Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T-cells from immune and early tumor-bearing host spleens.”Cancer Res. Apr;46(4 Pt 1):1805-12.
Bernhard et al. (2002) “Vaccination against the HER-2
eu oncogenic protein.”Endocrine-Related Cancer, 9:33-44.
Bielecki et al. (1990) “Bacillus subtilis expressing a haemolysin gene from Listeria monocytogenes can grow in mammalian cells”Nature354:175-176.
Billington et al. (1997) “The Arcanobacterium (Actinomyces) pyogenes hemolysin, pyolysin, is a novel member of the thiol-activated cytolysin family.”J Bacteriol. Oct;179(19):6100-6.
Bodmer et al. (1988) “Enhanced recognition of a modified peptide antigen by cytotoxic T cells specific for influenza nucleoprotein.”Cell52: 253-258.
Boon et al. (2006) “Human T cell responses against melanoma”Annu Rev lmmunol. 24:175-208.
Bourquin et al. (2000) “Myelin oligodendrocyte gl
Paterson Yvonne
Singh Reshma
Cohen Mark S.
Harris Alana M.
Holleran Anne L
Pearl Cohen Zedek Latzer LLP
The Trustees of the University of Pennsylvania
LandOfFree
Listeria -based and LLO-based vaccines does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Listeria -based and LLO-based vaccines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Listeria -based and LLO-based vaccines will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4152189